- Home
- CNF vs NRXS Comparison
CNF vs NRXS Comparison
Compare CNF & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CNF | NRXS |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.5M | 49.0M |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CNF | NRXS |
|---|---|---|
| Price | $5.66 | $4.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 9.4K | ★ 151.4K |
| Earning Date | 02-27-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,241,013.00 | $3,362,320.00 |
| Revenue This Year | $252.34 | $31.05 |
| Revenue Next Year | N/A | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.89 |
| 52 Week Low | $2.36 | $1.33 |
| 52 Week High | $13.90 | $6.20 |
Technical Indicators
Market Signals| Indicator | CNF | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 59.73 |
| Support Level | $4.00 | $4.33 |
| Resistance Level | $4.80 | $5.05 |
| Average True Range (ATR) | 0.49 | 0.33 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 82.96 | 45.40 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).